The US on Friday approved the first blood test for Alzheimer's, a move that can help patients begin treatment earlier with ...

The FDA-approved monoclonal antibody infusion known as donanemab, is showing promise to reduce cognitive decline among ...

The United States on Friday approved the first blood test for Alzheimer's, a move that could help patients begin treatment ...

Alzheimer's disease, a relentless condition that steals memory and independence, now has a powerful new opponent: donanemab (brand name Kisluna ). This newly approved intravenous ...

Donanemab – one of the first drugs to slow down early-stage Alzheimer’s disease – will not be available on the NHS in ...

Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, ...

Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

This groundbreaking research reveals that subtle chemical changes in tau may quietly set off a chain reaction, spreading ...

SEATTLE — There's new hope for people in the early stages of Alzheimer's disease. A new medication called donanemab appears to slow memory loss, giving patients the gift of more time.

Donanemab’s arrival in clinics marks another big moment in the fight against Alzheimer’s and dementia, one that makes Grabowski feel like “we’re just hitting our stride with this.” ...

LEXINGTON For the past four decades, the University of Kentucky's Sanders-Brown Center on Aging (SBCoA) has been at the ...

Alzheimer’s disease, a relentless condition that steals memory and independence, now has a powerful new opponent: donanemab (brand name Kisluna). This newly approved intravenous (IV) infusion ...